-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The purpose of this study was to assess the effects of avogo-derived fatty acid oxidation (FAO) inhibitor AvoB on glucose and fat metabolism in diet-induced obesity (DIO) models and in vitro fat toxicity models.
, the study also determined its safety in humans, and the results have been published online in Mol Nutr Food Res.
gave mice a high-fat diet (HFD) for 8 weeks.
, oral AvoB or vehicle is served twice a week for 5 weeks.
results showed that AvoB inhibited FAO, resulting in improved glucose tolerance, glucose utilization and insulin sensitivity.
the effects of AvoB on the metabolism of β cells and C2C12 muscle tubes in in-body.
found that AvoB inhibited FAO, increased glucose oxidation, leading to a decrease in mitochondrial reactive oxygen species, respectively, to improve the insulin response of the C2C12 muscle tube and insulin secretion of INS-1 (832/13) cells.
researchers conducted a randomized, double-blind, placebo-controlled clinical trial in healthy human participants to assess the safety of taking AvoB (50 mg or 200 mg per day for 60 days).
found that AvoB was well-to-do and not accompanied by any dose-limiting toxicity.
, the results show that there are currently no safe and effective drugs to suppress FAO and improve THEO-related pathology.
AvoB's mechanism of function and good safety highlight its nutritional and clinical importance.
.